28 children, treated with gentamicin during the newborn period, were examined at the age of 2–3¾ years for the possible impairment of vestibular, cochlear or renal function. Five of the children showed lesions of the hearing and/or vestibular function, and one, possibly, had slight renal tubular insufficiency. In this case, and in 3 of the otologic cases, there were other, clearly more probable causes of the lesions than gentamicin, and we feel justified in excluding gentamicin as an etiological factor in these cases. In the 2 remaining cases, however, no definite conclusion can be drawn as to the possible role of gentamicin in the pathogenesis of the lesions. One of these cases is a boy who had been slightly asphyctic after birth, suffered a virogenic meningitis at the age of 2 weeks, and had a slight cerebral concussion at the age of 10 months. He had a slight vestibular dysfunction. The other case is a girl who was premature, had hypoglycaemia, and septicaemia. She had severe loss of hearing and possibly a slight vestibular dysfunction, but no other neurological signs. Neither of these 2 children have received other ototoxic antibiotics.

Keywords:
Gentamicin, adverse effects, Infant, newborn, Infection
This content is only available via PDF.
© 1973 S. Karger AG, Basel
1973
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.